公开(公告)号：US20230088070A1

公开(公告)日：2023-03-23

申请号：US17728265

申请日：2022-04-25

Applicant: NOVARTIS AG

Inventor： Andreas BRUEDERLE ,  Anshu MARATHE ,  Jean REGARD ,  Mikael Lee RINNE ,  Haiying SUN ,  K. Gary J. VANASSE ,  Connie WONG

IPC: C07K16/24 ,  A61P35/04 ,  C07K16/28

Abstract: Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.

公开(公告)号：US20240025993A1

公开(公告)日：2024-01-25

申请号：US18035470

申请日：2021-11-04

Applicant: NOVARTIS AG

Inventor： Regis CEBE ,  Dattananda CHELUR ,  Brian Walter GRANDA ,  Connie WONG ,  Sunyoung JANG ,  Haihui LU ,  Amy RAYO ,  Darko SKEGRO

IPC: C07K16/28 ,  A61P35/00

CPC classification number: C07K16/2803 ,  A61P35/00 ,  C07K2317/565 ,  C07K2317/52 ,  C07K2317/31 ,  C07K2317/35 ,  C07K2317/622 ,  C07K2317/55

Abstract: The present disclosure provides CD19 binding molecules that specifically bind to CD19, including monospecific, bispecific and trispecific binding molecules, conjugates comprising the CD19 binding molecules, and pharmaceutical compositions comprising the CD19 binding molecules and the conjugates. The disclosure further provides methods of using the C19 binding molecules to treat diseases and disorders associated with expression of CD19. The disclosure yet further provides recombinant host cells engineered to express the CD19 binding molecules and methods of producing the CD19 binding molecules by culturing the host cells under conditions in which the CD19 binding molecules are expressed.

公开(公告)号：US20220056123A1

公开(公告)日：2022-02-24

申请号：US17415298

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Mark SHILKRUT ,  Michelle TSAI ,  Connie WONG

IPC: C07K16/24 ,  A61K45/06 ,  A61P35/04

Abstract: Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of a cancer having at least a partial inflammatory basis.

公开(公告)号：US20220025036A1

公开(公告)日：2022-01-27

申请号：US17415284

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Paola AIMONE ,  Connie WONG

IPC: C07K16/24 ,  A61P35/02 ,  A61K31/455 ,  A61K31/337 ,  C07K16/28 ,  A61K39/395

Abstract: Use of an IL-Iβ binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment of cancer with at least partial inflammatory basis, e.g., CML.

公开(公告)号：US20200369762A1

公开(公告)日：2020-11-26

申请号：US16719154

申请日：2019-12-18

Applicant: NOVARTIS AG

Inventor： Andreas BRUEDERLE ,  Anshu MARATHE ,  Jean REGARD ,  Mikael RINNE ,  Haiying SUN ,  K. Gary J. VANASSE ,  Connie WONG

IPC: C07K16/24 ,  C07K16/28 ,  A61P35/04

Abstract: Use of an IL-1β binding antibody or a functional fragment thereof, especially canakinumab or a functional fragment thereof, or gevokizumab or a functional fragment thereof, and biomarkers for the treatment and/or prevention of cancer with at least partial inflammatory basis, e.g., MDS.